Biological risk assessment and management is our tool to foster the positive impact of the advancement of bioscience and biotechnology for society.

S1 Adapted solutions for
biorisk management

S2 Evaluation of new
techniques and
environmental risk
assessment

S3 Applicable misuse
prevention and
biosecurity

S4 Promotion of global
biosafety and biosecurity

S5 Mentoring of biosafety
and biosecurity
professionals

S6 Public communication
and open-space
biosafety

Us and our partnering network

During our 20 years of business, we have consequently and consistently built and maintained our partnership with experts and partnering networks internationally.

Efficacy of COVID-19 vaccines and why they are so difficult to compare

Mrz 10 2021
With a number of COVID-19 vaccines on the market what does it mean if I’m vaccinated by one or the other vaccine?

Vaccine combinations against SARS-CoV-2

Februar 18 2021
What an amazing wealth of different types of vaccines against...

Biosafety & Biosecurity Management at Stanford University

Januar 22 2021
As a former Stanford Post Doc I have been...
Go to Blog
«Jenal & Partners with their large knowledge and experience have improved our biosafety procedures significantly not only regarding safety, but also regarding sustainability and economical aspects. Most importantly though, communication, information transfer and review processes with all stakeholders assure consensus building, understanding and voluntary adoption of our biosafety procedures.»
Thomas Moser, Head Health Safety Security & Environment, Idorsia Pharmaceuticals Ltd. Allschwil, Switzerland
«Jenal & Partners have supported us for an urgent project with their professional expertise regarding environmental risk assessments, and this on very short notice. Their concise and efficient work allowed us to stay on track with our programme. The friendly communication style and a profound understanding of the field made the project successful and the collaboration highly enjoyable.»
Florence Salmon, former Portfolio Head Regulatory Affairs CMC, Cell and Gene Therapies at Novartis, Switzerland